References
- Cometta A, Calandra T, Gaya H et al. Monotherapy with Meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrobial Agents and Chemotherapy 1996; 40: 1108–1115.
- Oppenheim BA, Morgenstern GR, Chang J et al. Safety and efficacy of piperacillin/tazobactam versus meropenem in the treatment of febrile neutropenia. Proceedings of 7th Conference of the Federation of Infection Societies 2000, P67, 52.
- Smyth ETM, Barr JG, O’Neill CA, Hogg GM. An assessment of the hidden and total antibiotic costs of four parenteral cephalosporins. PharmacoEconomics 1995; 8: 540–550.
- Smyth ETM, Barr JG, Hogg GM. An assessment of hidden costs on total prescribing costs of courses of meropenem and imipenem/cilastatin. British Journal of Medical Economics 1996; 10: 325–340.
- Anatomical, Therapeutic, Chemical (ATC) Classification Index including Defined Daily Doses (DDD). WHO Collaborating Centre for Drug Statistical Methodology, 2000.